← Search & browse all drugs
ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS › ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS › ECTOPARASITICIDES, INCL. SCABICIDES › Pyrethrines, incl. synthetic compounds
permethrin, combinations
P03AC54
Forms & Strengths
- Topical cream: permethrin 1% to 5%
- Topical lotion: permethrin 1% to 5%
- Aerosol spray/liquid combinations (often with piperonyl butoxide) for lice and scabies
Adult Dosing
- Scabies (5% cream): Apply thoroughly from head to soles of feet, leave on for 8-14 hours, then wash off. Single application usually curative.
- Pediculosis (1% liquid/cream/lotion): Apply to dry hair, saturate hair and scalp, leave on for 10 minutes, then rinse thoroughly.
Pediatric Dosing
- Scabies (infants >= 2 months and children): Apply 5% cream similarly to adults; for infants, apply to scalp, temple, and forehead as well.
- Pediculosis (pediatric patients >= 2 months): Apply 1% formulation to dry hair, leave for 10 minutes, rinse thoroughly.
Indications
- Treatment of infestation with Sarcoptes scabiei (scabies)
- Treatment of head lice (Pediculus humanus capitis) and their nits (in combination products)
Mechanism of Action
- Acts on nerve cell membranes to disrupt the sodium channel current by which the polarization of the membrane is regulated
- Causes delayed repolarization and paralysis of the pest (parasite/louse/mite), leading to death
Contraindications
- Hypersensitivity to permethrin, pyrethrins, chrysanthemum or ragweed allergens, or any component of the formulation
- Use on children younger than 2 months of age (unless directed by a physician)
Adverse Reactions
- Pruritus (may persist for weeks after successful scabies treatment due to allergic response to dead mites)
- Erythema, rash, or localized swelling
- Stinging, burning, or tingling at application site
- Numbness of the scalp (when used for head lice)
Drug Interactions
- Topical corticosteroids: May exacerbate manifestations of scabies by suppressing the immune/inflammatory response (avoid concurrent use if possible)
- No significant systemic pharmacokinetic drug interactions due to minimal percutaneous absorption
Curated Content: Needs Vetting Before Put to Clinical Use